PROSTATE SPECIFIC ANTIGEN

The rate of Prostate cancer occurrence is increasing at an alarming rate in recent years. A large number of people are termed victims to this disease every year. However, there is some good news to our relief, the first cancer vaccine to treat people with prostate cancer has been evaluated. The US government has nodded its head for the release of this vaccine and this drug has also been approved by the FDA (US Food and Drug Administration). If the patient is administered with the prostate vaccine, it can only prolong their life for a short period. Unfortunately, it does not offer a complete cure.

The newly developed vaccine is called Provenge, and was developed by Dendreon Pharmaceuticals. The drug is not a preventive medicine, like other vaccines, which are administered to protect the body from an infection. The innovative vaccine is used in post-diagnosis treatment. Although insignificant to some, this drug has prolonged the life of the victims by up to four months. Moreover it has fewer side effects when compared with the chemotherapy. Provenge works with patients in whom the hormone therapy fails to work. Three shots of treatment with Provenge would cost about $93,000. The rate of success with this vaccine is very low.

So it is better to prevent the the possibility of acquiring prostate cancer than to undergo risky treatment methods. Persons over the age of thirty five should be cautious and regularly screened for PSA (Prostate Specific Antigen) in the blood. Work with your doctor and gain the knowledge necessary to be proactive with a program like our PSA ZERO. Avoid prostate cancer and the related complications as for the treatments are extremely risky and have proven to be arguably of little benefit. Keep this disease away and preserve the precious biological functions of the prostate gland. After all you deserve to live your life as healthy as possible.